The conversion guidance that exists for transitioning between other GLP-1 agonists can provide some framework for thinking about dosing during transitions, though no specific tirzepatide-to-retatrutide conversion protocol has been established in clinical literature
Thyroid Health: A major contraindication for any glp-1 receptor agonist (including dual and triple agonists) is a personal or family history of Medullary Thyroid Carcinoma (MTC)
This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic
Like liraglutide, semaglutide incorporates an Aib substitution at the 8th position in place of Ala, which confers resistance to enzymatic degradation by DPP-4
Any manufacturer involvement or COI
What Does Retatrutide Actually Treat